Skip to main content

CSL Coronavirus Information

We are committed to continuing to provide our medicines to patients around the world, while pursuing COVID-19 treatments through a variety of collaborations.

Infographic showing the road to manufacturing of the CSL AstraZeneca COVID19 Vaccine

Overview: Manufacturing and Quality Testing a COVID-19 Vaccine at CSL

We've created an infographic to help understanding of the manufacturing and quality testing processes involved in making a COVID-19 vaccine at CSL.

View the COVID-19 Vaccine Infographic

News Releases & Updates

COVID-19 Update

24 JUNE 2022: CSL continues to provide medicines to patients around the world.


CoVIg-19 Plasma Alliance: Topline Results from Trial of Investigational COVID-19 Hyperimmune Globulin Medicine

2 APRIL 2021: Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial did not meet its endpoints to show efficacy in adults hospitalized with COVID-19.

CSL’s Global Role in Battling COVID-19

2 APRIL 2021: Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19.


First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

8 OCTOBER 2020: The anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19.

The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate

5 JUNE 2020: CEPI, the Coalition for Epidemic Preparedness Innovations, CSL (ASX:CSL) and The University of Queensland (UQ) today announced that they have entered into a new, significant partnering agreement to accelerate the development, manufacture and distribution of a COVID-19 vaccine candidate which has been pioneered by researchers at UQ.


CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic

8 APRIL 2020: COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer.


Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

6 APRIL 2020: Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19.